- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03391297
Shortened Prolonged Exposure Therapy for Chronic PTSD in Taiwanese Adults
Shortened Prolonged Exposure Therapy for Chronic PTSD: A Systematic Case Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Posttraumatic stress disorder (PTSD) is a common psychological disorder following trauma and disaster. Due to the frequent occurrence of disasters induced by natural hazards, many Taiwanese people suffer from post-disaster mental health problems, suggesting the necessity of promoting evidence-based psychotherapies for PTSD in Taiwan. However, there has been little concern about this necessity over the past decades. To date, several evidence-based psychotherapies for PTSD have been developed, and prolonged exposure treatment (PE) has the largest number of studies supporting its efficacy and effectiveness. PE has been found effective with the widest range of trauma populations and has been studies across cultures. Given its strong evidence base, the investigators tested the efficacy and feasibility of PE for Taiwanese PTSD patients. It is noted that the original length of PE session is 90 minutes, which is difficult to get reimbursement by insurance and may prevent mental health professionals to use PE. Recent researchers shortened the length of PE session to 60 minutes and found its efficacy was non-inferior to standard 90-minute PE session (Nacasch et al., 2015; van Minnen & Foa, 2006). Accordingly, this study aims to examine the efficacy of 60-minute PE sessions versus standard 90-minute session for patients with PTSD in Taiwan.
Study Hypothesis: (a) 60-minute PE session is as effective as 90-minute PE session in reducing PTSD and depressive symptoms as well as in promoting posttraumatic growth (PTG); and (b) the treatment gains will be maintained at 3-month follow-up. A systematic case study will be employed to test the hypotheses.
Participants: Participants will include eight individuals aged 18 or older who meet a diagnosis of DSM-5 PTSD and to experience moderate to severe symptoms for at least 3 months. Those who have current substance dependence, psychosis, and acute suicidality (i.e., recent suicidal ideation with intent and plan) will be excluded.
Study Design: All enrolled participants will attend 10-15 weekly 60- or 90-minute PE sessions. Independent evaluators will assess PTSD diagnosis using the PTSD Symptoms Scale Interview for DSM-5 (PSSI-5) at pre- and post-treatment and at the three-month follow-up. Psychiatric comorbidity will be assessed using the MINI 7.0.2 at pretreatment. Participants will complete the Posttraumatic Diagnostic Scale for DSM-5 (PDS-5), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), Posttraumatic Cognitions Inventory (PTCI), and Posttraumatic Growth Inventory -Extended version (PTGI-X) at pre- and post-treatment and at the three-month follow-up. The PDS-5 and BDI-II will also be administered every two weeks during treatment.
Statistical Analysis: The nonparametric tests will be used given the small sample size. Wilcoxon signed-rank test will be conducted to test pre-post differences. Mann-Whitney U test will be conducted examine whether 60-minute PE session is as effective as 90-minute PE session in reducing PTSD and depressive symptoms as well as increasing PTG at post-treatment and three-month follow-up.
Expected Outcome: The investigators except that shortened PE will result in substantial improvement in PTSD and depressive symptoms in patients with PTSD in Taiwan.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yi-Jen Su, Ph.D.
- Phone Number: 3421 +886-3-2118800
- Email: suyijen@mail.cgu.edu.tw
Study Locations
-
-
Guishan Dist.
-
Taoyuan, Guishan Dist., Taiwan, 33302
- Recruiting
- Graduate Institute of Behavioral Sciences, Chang Gung University
-
Contact:
- Yi-Jen Su, Ph.D.
- Phone Number: 3421 +886-3-2118800
- Email: suyijen@mail.cgu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- primary diagnosis of DSM-5 PTSD, with moderate to severe symptoms for at least 3 months
Exclusion Criteria:
- organic mental disorder, current substance dependence, psychosis, acute suicidality (i.e., suicidal ideation with intent and plan), and severe dissociation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 60-minute Prolonged Exposure Therapy
This condition is a modified version of Prolonged Exposure Therapy for PTSD.
It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
|
PE consists of 10-15 treatment sessions.
Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
|
ACTIVE_COMPARATOR: 90-minute Prolonged Exposure Therapy
This condition is standard Prolonged Exposure Therapy.
It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
|
PE consists of 10-15 treatment sessions.
Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interviewer-assessed PTSD diagnosis and symptoms
Time Frame: Pre-treatment through three-month follow-up
|
as measured by the Chinese version of the PTSD Symptoms Scale Interview for DSM-5 (PSSI-5) (Foa et al., 2016).
The tota score ranged from 0 to 80, with higher scores indicating greater PTSD symptoms.
|
Pre-treatment through three-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported PTSD symptoms
Time Frame: Pre-treatment through three-month follow-up
|
as measure by the Chinese version of the Posttraumatic Diagnostic Scale for DSM-5 (PDS-5; Foa et al., 2016).
The tota score ranged from 0 to 80, with higher scores indicating greater PTSD symptoms.
|
Pre-treatment through three-month follow-up
|
Self-reported depressive symptoms
Time Frame: Pre-treatment through three-month follow-up
|
as measure by the Chinese version of the Beck Depression Inventory-II (Beck, Steer, & Brown, 1996).
The tota score ranged from 0 to 63, with higher scores indicating greater depressive symptoms.
|
Pre-treatment through three-month follow-up
|
Self-reported posttraumatic growth
Time Frame: Pre-treatment through three-month follow-up
|
as measured by the Chinese version of the Expanded Posttraumatic Growth Inventory.
The total score ranged from 0 to 75, with higher scores indicating greater trauma-related growth.
|
Pre-treatment through three-month follow-up
|
Self-reported posttraumtic negative cognitions
Time Frame: Pre-treatment through three-month follow-up
|
as measured by the Chinese version of the Posttraumatic Cognition Inventory.
The total score ranged from 33 to 231, with higher scores indicating greater posttraumatic negative cognitions.
|
Pre-treatment through three-month follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yi-Jen Su, Ph.D., Chang Gung University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOST 106-2628-H-182-001-SS2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorder
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Icahn School of Medicine at Mount SinaiCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Berlin Center for the Treatment of Torture VictimsCompletedPosttraumatic Stress Disorder (PTSD)Germany
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Center for PTSDCompletedPosttraumatic Stress Disorder (PTSD)United States
Clinical Trials on Prolonged Exposure Therapy
-
University of PennsylvaniaMedical University of South Carolina; U.S. Army Medical Research and Development...CompletedPosttraumatic Stress Disorder | Combat DisorderUnited States
-
Emory UniversityCenters for Disease Control and PreventionWithdrawnPost Traumatic Stress Disorder, PTSD
-
Baylor Research InstituteActive, not recruitingSpinal Cord Injuries | Posttraumatic Stress DisorderUnited States
-
Veterans Medical Research FoundationUniversity of Pennsylvania; United States Department of DefenseCompletedDepression | Posttraumatic Stress Disorders | AnxietyUnited States
-
Veterans Medical Research FoundationUniversity of Minnesota; Center for Veterans Research and EducationNot yet recruitingStress Disorders, Post-Traumatic | Substance Use DisordersUnited States
-
University of PennsylvaniaCompletedPTSD | Posttraumatic Stress DisorderUnited States
-
Rabin Medical CenterUnknownPTSD | Traumatic Brain Injury | Post Concussive SyndromeIsrael
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedPost-Traumatic Stress DisorderUnited States
-
Kent State UniversityNational Institute of Mental Health (NIMH); Summa Health SystemUnknownHIV Infections | Stress Disorders, Post-TraumaticUnited States